Head to Head Analysis: Trevena (TRVN) and Its Rivals
Trevena (NASDAQ: TRVN) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Trevena to similar companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.
Valuation and Earnings
This table compares Trevena and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trevena||$3.75 million||-$102.99 million||-1.07|
|Trevena Competitors||$290.27 million||$35.99 million||53.49|
This is a summary of recent recommendations and price targets for Trevena and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trevena presently has a consensus target price of $8.65, suggesting a potential upside of 390.61%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.00%. Given Trevena’s stronger consensus rating and higher possible upside, research analysts clearly believe Trevena is more favorable than its peers.
Institutional & Insider Ownership
56.1% of Trevena shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.6% of Trevena shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Trevena and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Trevena has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Comparatively, Trevena’s peers have a beta of 2.25, meaning that their average stock price is 125% more volatile than the S&P 500.
Trevena peers beat Trevena on 8 of the 13 factors compared.
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.